Steve M. Winder
Steve M. Winder
Regional Managing Partner at Borden Ladner Gervais LLP (BLG)
(604) 687-5744
(604) 687-1415
200 Burrard St, Suite 1200, Waterford Centre, Vancouver, BC
Year called to bar: 1996
Steve Winder is a partner in the BLG Vancouver office and regional group manager of the Labour and Employment Group. Steve provides labour and employment advice and representation for unionized workforces, including in grievance arbitrations, matters before the Labour Relations Board, and collective bargaining. He has experience dealing with post-termination matters, including bringing and defending non-competition injunctions. His broad expertise includes dismissals and discipline; employment contracts and policies; collective agreements and bargaining; human rights issues; employment standards; privacy; and WorkSafe matters. Steve has acted as counsel in the Provincial, Supreme Court, and Court of Appeal for British Columbia, and before the Human Rights Tribunal, Labour Relations Board, Workers Compensation Appeal Tribunal, Employment Standards Tribunal, and Employment Insurance Commission. He is recognized in the 2021 edition (since 2018) of Chambers Canada – Canada's Leading Lawyers for Business, the 2021 edition (since 2014) of The Best Lawyers in Canada, the 2020 edition (since 2017) of Benchmark Canada – The Definitive Guide to Canada's Leading Litigation Firms & Attorneys as Local Litigation Star: British Columbia, and, in 2017, as Litigation Star: Labour and Employment.
Steve M. Winder is a featured Leading Lawyer in:
Canadian Legal Lexpert Directory
Repeatedly Recommended
Read more about Steve M. Winder in ...
On April 12, 2018, Arbutus Biopharma Corporation (Arbutus), an industry-leading hepatitis B virus (HBV) therapeutic solutions company, and Roivant Sciences Ltd. (Roivant) announced that they have entered into an agreement to launch Genevant Sciences (Genevant), a jointly-owned company focused on the discovery, development, and commercialization of a broad range of RNA-based therapeutics. Under the terms of the agreement, Roivant will contribute US$37.5 million in transaction-related seed capital for Genevant.